Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2009

View Archived Issues

GSK-2126458 shows potent preclinical antitumor activity; phase I trial under way

New camptothecin conjugate evaluated in phase I trial in advanced solid tumors

FIELD trial data support beneficial effects of fenofibrate in type 2 diabetes patients

Prasugrel more effective than clopidogrel in CAD patients with type 2 diabetes

Small-molecule compound BRA-101 reduces DSS-induced murine colitis

Novel AR antagonist ZR-291 exhibits potent preclinical activity in prostate cancer

Novartis' Onbrez Breezhaler approved in E.U. for patients with COPD

Daiichi Sankyo reports results from Q2 of 2009, ended September 30

Vertex reports results from third quarter of 2009

MicroDose Therapeutx acquires EPX-16006 from Epix

Johnson & Johnson submits NDA to FDA for tapentadol ER tablets for chronic pain

New recombinant Xyntha now available in Canada

Stryker agrees to acquire Ascent Healthcare Solutions

DiaMedica expands into neurological disorders through acquisition of Sanomune

Pacira reports results of phase III Exparel trial in postoperative pain

Roche reports encouraging results from phase III trials of taspoglutide in diabetes

Javelin submits NDA to FDA for Dyloject for acute moderate to severe pain in adults

Watson Pharmaceuticals acquires Arrow Group

Bayer Schering Pharma claims novel series of adenosine A1 agonists

Novel antibacterial agents disclosed by AstraZeneca

Merck & Co. describes beta3-adrenoceptor agonists for urinary incontinence

Agreement reached on U.S. approval pathway for Pompe disease treatment

Endo provides regulatory update on Aveed for men with low testosterone

FDA approves AstraZeneca's Seroquel for pediatric schizophrenia and bipolar mania

ExonHit Therapeutics launches AclarusDx Alzheimer's test

Epigallocatechin gallate possibly beneficial in open-angle glaucoma patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...